78056-28-7

Basic information

• Product Name: AKOS BC-0240
• Synonyms: AKOS BC-0240;1-AMINO-3-METHYLADAMANTANE;Tricyclo[3.3.1.13,7]decan-1-amine, 3-methyl-;3-Methyladamantan-1-amine
• CAS NO: 78056-28-7
• Molecular Formula: C₁₁H₁₉N
• Molecular Weight: 165.278
• Mol File: 78056-28-7.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 232.206 °C at 760 mmHg
• Flash Point: 93.343 °C
• Appearance: /
• Density: 1.056 g/cm³
• PKA: 10.78±0.40(Predicted)
• CAS DataBase Reference: AKOS BC-0240(CAS DataBase Reference)
• NIST Chemistry Reference: AKOS BC-0240(78056-28-7)
• EPA Substance Registry System: AKOS BC-0240(78056-28-7)

Safety Data

• Hazardous Substances Data: 78056-28-7(Hazardous Substances Data)

Usage

General Description

AKOS BC-0240 is a chemical compound that is also known as (R)-N-((S,E)-4-(1-acetylpiperidin-4-yl)-3-methoxyphenyl) ethanesulfonamide. It is a white to off-white powder that is soluble in organic solvents such as DMSO. AKOS BC-0240 is a potential intermediate in the synthesis of pharmaceuticals and other organic compounds. It has also been studied for its potential use as an inhibitor of certain biological processes, although its specific applications and mechanisms of action are not fully understood. Overall, AKOS BC-0240 is a versatile chemical compound with potential applications in both research and industrial processes.

InChI:InChI=1S/C11H19N/c1-10-3-8-2-9(4-10)6-11(12,5-8)7-10/h8-9H,2-7,12H2,1H3

Upstream product

• 702-77-2 1-bromo-3-methyladamantane 
• 768-91-2 1-methyl-adamantane 
• 702-81-8 3-methyl-1-adamantanol 
• 778-09-6 1-acetamido-3-methyltricyclo[3.3.1.1^3,7]decane 

Downstream Products

• 99998-84-2 N'--N-<3-methyl-adamantyl>-harnstoff 

Relevant articles and documents

Structure-Anti-Parkinson Activity Relationships in the Aminoadamantanes. Influence of Bridgehead Substitution

A limited series of bridgehead alkyl-, dialkyl- and trialkyl-substituted amantadines was synthesized and tested for potential anti-Parkinson activity as dopamine (DA) agonists.The compounds were evaluated using a battery of three murine bioassays, including stimulation of locomotor activity, induction of circling in animals with unilateral striatal lesions, and reversal of reserpine/α-methyltyrosine induced akinesia.Apparent mechanistic differences were seen between the methyl-substituted series and the ethyl-substituted series.While activities in both series increase with increasing liphophilicity, the methyl series (1b-d), as well as amantadine itself (1a) exhibits only indirect DA agonist activity, as evidenced by ipsilateral rotation in the circling model and no significant difference from control in reversal of akinesia.The ethyl series (1e,f) exhibits weak but reprodicible direct DA agonist activity, as shown by contralateral rotation in the circling assay for 1e and reversal of akinesia by 1e and 1f.The 3-n-propyl derivative (1g) was devoid of any DA agonist activity.